Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant <i>APC</i> and <i>TP53</i> Subpopulations

201922 citationsJournal Articlebronze Open Access

Authors

These findings, if further validated through clinical trials, could also expand the utility of EGFRi therapies that are currently underutilized.

Good health and well-being

Published in: Cancer Epidemiology Biomarkers & Prevention

Volume 28, Issue 7, pp. 1141-1152

Field-Weighted Citation Impact: 1.31